Literature DB >> 15920331

What do patients want from their acute migraine therapy?

Michel Lantéri-Minet1.   

Abstract

A minority of migraine sufferers are diagnosed and treated and medical consultation rates are low even among those aware of their condition. Despite guidelines recommending the use of triptans, there are high rates of usage of nonspecific treatments, mainly simple analgesics, coupled with low prevalence of triptan use. Consequently, many individuals with migraine are not receiving the kind of treatment that would meet their expectations and leave them satisfied. For patients, the most important attributes of acute migraine treatment are complete freedom from pain, rapid onset of action, no recurrence and absence of side effects. More widespread use of triptans would have the potential to improve outcomes and increase patient satisfaction, leading to a better migraine-related quality of life. In choosing among triptans, physicians need to match individual patients' needs and wants with the attributes of the particular triptans, taking into account a medication's complete profile of efficacy, consistency and tolerability, and using information from meta-analyses and modelling to ensure evidenced-based, patient-oriented decision-making.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920331     DOI: 10.1159/000085036

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  7 in total

1.  Fixed-dose Sumatriptan/Naproxen Sodium Compared with each Monotherapy Utilizing the Novel Composite Endpoint of Sustained Pain-free/no Adverse Events.

Authors:  Stephen Landy; Jonathan White; Shelly E Lener; Susan A McDonald
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

2.  Comparison of expected outcomes between patients and neurologists using Kano's methodology in symptomatic migraine treatment.

Authors:  J Matías-Guiu; M T Caloto; G Nocea
Journal:  Patient       Date:  2012       Impact factor: 3.883

Review 3.  What can be learned from the history of recurrence in migraine? A comment.

Authors:  Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-08-25       Impact factor: 7.277

4.  Relevance of absorption rate and lag time to the onset of action in migraine.

Authors:  Hugo J Maas; Marc A H Spruit; Meindert Danhof; Oscar E Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea.

Authors:  Byung-Kun Kim; Min Kyung Chu; Soo Jin Yu; Grazia Dell'Agnello; Jeong Hee Han; Soo-Jin Cho
Journal:  J Headache Pain       Date:  2021-05-24       Impact factor: 7.277

6.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

7.  Efficacy of frovatriptan as compared to other triptans in migraine with aura.

Authors:  Stefan Evers; Lidia Savi; Stefano Omboni; Carlo Lisotto; Giorgio Zanchin; Lorenzo Pinessi
Journal:  J Headache Pain       Date:  2015-04-01       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.